Moreover, newly approved selective JAK1 inhibitors, such as upadacitinib and filgotinib, drug-reported safety profile discloses an increased risk for invasive fungal infections, such as cryptococcosis and pneumocystis (upadacitinib only) and endemic mycosis infections, as well as an increased risk of neutropenia and lymphopenia (26, 27). Here, JAK1 is linked to lymphopenia.